Consensus CSL Limited

Stocks

CSL

AU000000CSL8

Pharmaceuticals

Market Closed - Australian S.E. 02:18:24 2026-09-24 EDT			5-day change	1st Jan Change
179.12 ^AUD	-0.07%		+0.88%	+3.75%

09-22	Csl Canada Expands Public Access to Andembry® Across Canada for the Prevention of Hereditary Angioedema Attacks	CI
09-21	Australian shares end flat as miners offset gains in banks	RE

Evolution of the Average Target: CSL Limited

Evolution of the Target Price: CSL Limited

Changes in Analyst Recommendations: CSL Limited

5d9660ff43dc434.bjOI4GnqABnwfo9IVWPyjyGo8mtIh-l6TVAwKJUPEGU.PWvEpjiQYVGEMdwJZSmGuXmbwhp-8I0VLhFmTN9IWw49WbixHIsyXrNGxg~ea147ead6ba646d3df488f25865dea30

Analysts' recommendations: CSL Limited

08-17	CSL's Fiscal 2026 Results In Line, Jefferies Says	MT
06-25	CSL, Plasma Industry Could Continue to Grow Strongly for Considerable Period, Jefferies Says	MT
05-11	CSL's Fiscal-Year Earnings Guidance Downgrade Not Surprising, Jefferies Says	MT
03-20	CSL's Business Not Threatened by CIDP Therapy Competition, Says Jefferies	MT
03-01	Organic Growth in Australia's Healthcare Services Likely Due to Increased Availability of Bulk-Billing General Practitioners, Jefferies Says	MT
02-10	CSL's Fiscal H1 EBIT Boosted by Cost Reductions, Jarden Says	MT
12-08	CSL's China Albumin Sale to Improve in Fiscal H2 2026, Says Jefferies	MT
11-10	CSL Impacted by Launch Delays, Vaccine Fatigue, Says Jefferies	MT
11-06	CSL Expected to See Potential Medium-Term Earnings Upside, Says Jefferies	MT
11-06	CSL's Horizon 2 Approach to 'Significantly' Boost Margins, Earnings, Jarden Says	MT
25-10-29	Jarden Research Adjusts CSL's Price Target to AU$287.14 from AU$304.17, Keeps at Overweight	MT
25-10-28	CSL Faces Macroeconomic Challenges, Will Take Time to Rerate, Says Jefferies, Shares Down 3%	MT
25-10-28	Canaccord Genuity Upgrades CSL to Buy from Hold; Price Target is AU$225	MT
25-10-28	CSL's Flu Revenue Impact for Northern Hemisphere Season Drives Guidance Downgrade, Jarden Says	MT
25-10-02	CSL to Benefit From Immunoglobin Sales Growth, Says Jefferies	MT
25-07-31	Carlisle Faces Downgrade From Loop Capital; Shares Fall	MT
25-07-11	CSL Shares Fall Amid Target Price Cut by Morgans Financial	MT
25-07-10	Morgans Financial Upgrades CSL to Buy from Add; Price Target is AU$303.70	MT
24-10-24	CSL's R&D Day "Uninspiring," Jarden Research Says	MT
24-09-08	CSL 'Strong Franchise in Medium Term' Amid Higher Fiscal 2024 Earnings, Jefferies Says	MT
24-09-04	Carlisle Expected to Show Solid Growth, Margin Expansion, Oppenheimer Says	MT
24-08-14	Jarden Research Adjusts CSL's Price Target to AU$329.62 From AU$305.34, Keeps at Overweight	MT
24-03-05	Morgan Stanley Adjusts CSL’s Price Target to AU$310 From AU$318, Keeps at Overweight	MT
24-02-13	Jarden Research CSL’s Price Target to AU$296.02 From AU$298.57, Keeps at Overweight	MT
24-02-12	Jarden Research Adjusts CSL’s Price Target to AU$298.57 From AU$316.16, Keeps at Overweight	MT

More recommendations

Biopharmaceuticals

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	CSL LIMITED					+0.04%
	REGENERON PHARMACEUTICALS, INC.					+6.12%
	MODERNA, INC.					-34.35%
	SAMSUNG BIOLOGICS CO.,LTD.					+44.41%
	UCB					+34.69%
	BIOGEN INC.					+4.68%
	INCYTE CORPORATION					+2.49%
	INNOVENT BIOLOGICS, INC.					+24.87%
	SWEDISH ORPHAN BIOVITRUM AB					+13.95%
	BRIDGEBIO PHARMA, INC.					+66.03%
	Average					+16.29%
	Weighted average by Cap.					+8.42%